ProImmune Pentamer Citations | Cancer

Further Publications citing Pro5® Pentamers by research topic

List of ProImmune Pentamers

Customer Research Case Studies

Cancer Publications citing the use of ProImmune Pentamers

Have you published a paper citing the use of ProImmune's products or services? If so, please send us a reprint as a PDF by e-mail to We will send you a bottle of Champagne to celebrate with! (Limited to 1 bottle per publication).


Cancer Publications

Abrahamsen, I. et al. (2012) T cells raised against allogeneic HLA‐A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells International Journal of Cancer 130:1821 [PubMedID:21630262]

Abrahamsen, I. et al. (2010) Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif. Leukemia. 24(11):1901-9. [PubMedID: 20844564]

A*02:01/SLFLGILSV (CD20)

Adamina et al (2009) Intranodal Immunization With a Vaccinia Virus Encoding Multiple Antigenic Epitopes and Costimulatory Molecules in Metastatic Melanoma.  Molecular Therapy 18:651 [PubMedID:19935776]

Adotevi, O. et al. (2010) Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. Blood. 115(15):3025-3032. [PubMedID: 20130242]

Ali et al (2009) In situ regulation of DC subsets and T cells mediates tumor regression in mice.  Science Translational Medicine 1:8ra19 [PubMedID:20368186]

Ali, OA. et al. (2009) Infection-mimicking materials to program dendritic cells in situ. Nature Materials. 8: 151-158. [PubMedID: 19136947]


Altvater et al (2011) Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens. Cancer Immunology & Immunotherapy epub ahead of print.

Andersen, MH. et al. (2009). Identification of heme-oxygenase-1-specific regulatory CD8+T cells in cancer patients. J. Clin. Invest. 119: 2245-2256.[PubMedID: 19662679]

A*02:01/QLFEELQEL (Heme -oxygenase-1)
A*02:01/ELAGIGILTV (MelanA/MART-1)
A*02:01/ILKEPVHGV (HIV-1 pol)
A*02:01/SLYNTVATL (HIV-1 gag)

Anderson et al. (2011) Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.  Cancer Immunology Immunotherapy 60:985. [PubMedID: 21461886]

Anderson et al. (2011) Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells. Cancer Immunology Immunotherapy 60:857. [PubMedID: 21400024]

Ansen, S. et al. (2008). Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin-21. Clin. Cancer Res. 14: 6125-6136 [PubMedID: 18829491]


Asprodites et al (2008) Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity FASEB J. 22:3628 [PubMedID:18587008]

Barnes, SE. et al. (2015) T cell-NF-κB activation is required for tumor control in vivo. Journal for ImmunoTherapy of Cancer. [PubMedID:25648675]

Becker et al. (2010) DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) Elicits Long-term T-cell Responses in Patients With Recurrent Prostate Cancer. Journal of Immunotherapy 33:689 [PubMedID:20551832]

Bellone, M. et al. (2010). iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells. PLoS ONE. 5: e8646. [PubMedID: 20072624]

H-2Kb/SIINFEKL (Ovalbumin)

Bergant, M. et al.(2006). Preparation of native and amplified tumour RNA for dendritic cell transfection and generation of in vitro anti-tumour CTL responses. Immunobiol. 211: 179-189. [PubMedID:16530085].


Bernstein et al (2012) First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. Journal of Translational Medicine. 10:156 [PubMedID:22862954]

Blotta et al (2009) Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance Blood 114:3276 [PubMedID:19587378]

Bonanno et al. (2012). Indoleamine 2,3-di-oxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. Journal of Translational Medicine 10: 247. [PubMedID: 23232072].


Bolonaki, I. et al. (2007). Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J. Clin. Oncol. 25: 2727-2734. [PubMedID: 17602077].

A*02:01/SMNTVATL (HIV gag)

Boozari, B. et al. (2010). Antitumoral immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma. Gut. 59:1416-1426. [PubMedID:20675696].


Bornhäuser et al. (2011). Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid. Blood. 117:7174. [PubMedID:21540460].

Bourquin, C. et al. (2008). Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J. Immunol. 181: 2990-2998 [PubMedID: 18713969]

H-2Kb/SIINFEKL (Ovalbumin)

Bracci, L. et al. (2008) Efficient stimulation of T cell responses by human IFN-a-induced dendritic cells does not require Toll-like receptor triggering. J Immunother. 31: 466-474. [PubMedID: 18463538]

A*02:01/ELAGIGILTV (MelanA/MART-1)
A*02:01/GILGFVFTL (Inlfuenza MP)

Brentville et al (2012) High Avidity Cytotoxic T Lymphocytes Can Be Selected into the Memory Pool but They Are Exquisitely Sensitive to Functional Impairment. PLoS One 7:e41112[PubMedID:22829916]

Brinkman et al (2005) Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma. Cancer Immunology Immunotherapy 54:611 [PubMedID: 15685447]

Britten, CM. et al. (2009). Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the cancer vaccine consortium. Cancer Immunol, Immunother. 58: 1701-1713.[PubMedID: 19259668]

A*02:01/GILGFVFTL (Influenza MP)
A*02:01/ELAGIGILTV (MelanA/MART-1)

Brown et al (2012) Loss of antigen cross-presentation after complete tumor resection is associated with the generation of protective tumor-specific CD8+ T-cell immunity. OncoImmunology 1:7

Buchert et al. (2010) Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia. Journal of Clinical Oncology 28:1489 [PubMedID:20142590]

Butler et al (2011) Establishment of Antitumor Memory in Humans Using in Vitro–Educated CD8+ T Cells. Science Translational Medicine 3: 80r34 [PubMedID: 21525398]

Calderhead, DM. et al. (2008). Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response. J Immunother. 31: 731-741. [PubMedID: 18779746]

A*02:01/ELAGIGILTV (MelanA/MART-1)

Camisaschi C. et al (2013) Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. Cancer Immunology Immunotherapy epub. [PubMedID:23589107]

Carnevale-Schianca, F. et al. (2006). Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood 107: 3795-3803. [PubMedID: 16403911]

A*02:01/NLVPMVATV(HCMV pp65)
A*02:01/ELAGIGILTV (MelanA / MART-1) - Negative control

Casado, JG. et al. (2009) Correlation of effector function with phenotype and cell division after in vitro differentiation of naive MART-1-specific CD8+ T cells. International Immunolgy. 21: 53-62.[PubMedID: 19050104]

A*02:01/ELAGIGILTV (MelanA/MART-1)

Cedeno-Laurent et al (2011) Metabolic Inhibition of Galectin-1-Binding Carbohydrates Accentuates Antitumor Immunity. Journal of Investigative Dermatology 132:410 [PubMedID:22158550]

Cerullo et al (2012) An Oncolytic Adenovirus Enhanced for Toll-like Receptor 9 Stimulation Increases Antitumor Immune Responses and Tumor Clearance. Molecular Therapy [PubMedID:22828500]

Cerullo et al (2010) Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients.  Cancer Research 70: 4297-4309 [PubMedID: 20484030]

A*02:01/LMLGEFLKL (Survivin)

Chaise, C. et al. (2008). DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood. 112: 2956-2964.[PubMedID: 18502835]

A*02:01/RMFPNAPYL (WT-1)
A*02:01/CMTWNQMNL (WT-1)

Chard, L et al (2014) A Vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer. Clinical Cancer Research. [Published online 21 November 2014][PubMedID: 25416195]

H-2Kb/TSYKFESV (vaccinia virus B8R/Ovalbumin)

Chiang et al (2006) Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells Cancer Immunology Immunotherapy 55:1384 [PubMedID:16463039]

Chiang, CL-L. et al. (2008). Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor. Clin. Cancer Res. 14: 4898-4907 [PubMedID: 18676764]

A*02:01/KIFGSLAFL (Her2/neu)

Ciesielski et al (2010) Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunology & Immunotherapy 59:1211 [PubMedID:20422411]

Clark et al (2007) Monocytes Immunoselected via the Novel Monocyte Specific Molecule, CD300e, Differentiate Into Active Migratory Dendritic Cells Journal of Immunotherapy 30:303 [PubMedID:17414321]

Cohen, C.J. et al. (2007). Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67: 3898-3903.[PubMedID: 17440104]

A*02:01/LLGRNSFEV (p53)

Cohen, C.J. et al.(2006). Enhanced antitumor activity of murine-human hybrid T cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.Cancer Res. 66: 8878-8886.[PubMedID:16951205]

A*02:01/LLGRNSFEV (p53)

Coleman J., et al (2010) Int J Cancer T cells reactive with HLA-A*0201 peptides from the histone demethylase JARID1B are found in the circulation of breast cancer patients. Epub [PubMedID:21105039]

A*02:01/LLLLTVLTV (Muc-1)

Coosemans, A. et al.(2010). Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Research.[PubMedID:20944158]

Cortez-Gonzalez et al (2010) Identification of Immunogenic Peptides of the Self-Tumor Antigen: Our Experience with Telomerase Reverse Transcriptase. Methods in Molecular Biology 651: 211 [PubMedID: 20686968]

Curti et al (2010) Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica 95:2022 [PubMedID:20801903]

Dai et al (2012) Early Treg suppression by a listeriolysin-O-expressing E. coli vaccine in heterologous prime–boost vaccination against cancer. Vaccine [PubMedID:22982404]

Dai et al. (2006). Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8+ CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells.  Journal of Molecular Medicine 84:1067.[PubMedID:17016692]

De Giovanni et al (2007) Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. International Journal of Cancer 121:88 [PubMedID:17290395]

DeBenedette, MA. et al. (2010). Potency of Mature CD40L RNA Electroporated Dendritic Cells Correlates with IL-12 Secretion Tracking Multifunctional CD8+/CD28+ Cytotoxic T-cell Responses In Vitro. Journal of Immunotherapy. 34(1): 45-57 [PubMedID: 21150712]

DeBenedette, MA. et al. (2008). Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent. J. Immunol. 181: 5296-5305 [PubMedID: 18832685]

A*02:01/ELAGIGILTV (MelanA/MART-1)

de Beukelaar, JW. et al. (2007) No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies. Cancer Immunol Immunother.56: 1501-1506. [PubMedID: 17597332]


Degl'Innocenti, E. et al. (2008). Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+/CD25+ regulatory T cells. Cancer Res. 68: 292-300. [PubMedID: 18172322]

H-2Kb/VVYDFLKL (SV40 T antigen)

Ding, C. et al. (2008) Targeting of antigens to B cells augments antigen-specific T cell responses and breaks immune tolerance to tumor-associated MUC1. Blood 112: 2817-2825 [PubMedID: 18669871]

H-2Kb/SIINFEKL (Ovalbumin)

Domschke, C. et al. (2009). Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res. 69: 8420-8428. [PubMedID: 19843863]

A*02:01/KIFGSLAFL (HER-2/neu)

Eissler et al (2012) Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect Cancer Research [PubMedID:22745368]

El-Jawhari, JJ et al (2014) Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes. Molecular Immunology. 58(2). pp160-168. [PubMedID: 24365750]

Escors, D. et al. (2008). Targeting dendritic cell signalling to regulate the response to immunisation. Blood. 111: 3050-61. [PubMedID: 18180378]

A*02:01/ELAGIGILTV (Melan-A/MART 1)

Evans et al (2012) EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing Sarcoma Family of Tumors. Clinical Cancer Research[PubMedID:22879388]

Fauquembergue, E., et al. (2010). HLA-A* 0201-restricted CEA-derived Peptide CAP1 Is Not a Suitable Target for T-cell-based Immunotherapy. Journal of Immunotherapy. 33(4): 402-413 [PubMedID:20386466]

Filipazzi et al (2012) Limited Induction of Tumor-cross-reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen-Class I-Modified Peptides. Clinical Cancer Research [PubMedID:23032742]

Fisher et al (2012) Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immology Immunotherapy [PubMedID:22406983]

Fontana et al (2009) Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. Blood 113:1651 [PubMedID:19074732]

Foster et al (2007) Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12. Journal of Immunotherapy 30:506 [PubMedID:17589291]

Foster, et al. (2010). Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia. 24(3):563-572 [PubMedID:20072155]


Freeman, JL. et al. (2007) CMRF-56 immunoselected blood dendritic cell preparations activated with GM-CSF induce potent antimyeloma cytotoxic T-cell responses. J Immunother. 30: 740-748. [PubMedID: 17893566]

A*02:01/ELAGIGILTV (MelanA/MART-1)

Fu et al. (2011) The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti–CTLA-4 Therapy. Cancer Research 71: 5545 [PubMedID: 21708958]

Gang et al. (2012) Efficient induction of specific cytotoxic T lymphocytes against gastric adenocarcinoma by a survivin peptide. Biochemistry and Cell Biology [PubMedID: 22992138]

Gehrmann, U. et al (2013) Synergistic induction of adaptive anti-tumour immunity by co-delivery of antigen with alpha-galactosylceramide on exosomes. Cancer Research epub ahead of print. [PubMedID:23658368]

H-2Kb/SIINFEKL (Ovalbumin 257-264)

Geiger, R. et al. (2009). Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. J. Exp. Med. 206: 1525-1534. [PubMedID: 19564353]

A*02:01/ELAGIGILTV (MelanA/MART-1)

Geng et al (2010) Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens. Cancer Research 70:7442 [PubMedID:20807806]

Ghosh, A. et al. (2008).Cytotoxic T cells reactive to an immunodominant leukemia-associated antigen can be specifically primed and expanded by combining a specific priming step with nonspecific large-scale expansion. J Immunother. 31: 121-131. [PubMedID:18481382]

H-2Kb/SIINFEKL (Ovalbumin)

Gitlin et al (2011) Melanoma differentiation-associated gene 5 (MDA5) is involved in the innate immune response to Paramyxoviridae infection in vivo. PloS Pathogens 6:e1000734 [PubMedID:20107606]

Gritzapis et al (2011) Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice. Cancer Immunology & Immunotherapy. epub ahead of print. [PubMedID: 21928125]

Gritzapis et al (2009) Peptide Vaccination Breaks Tolerance to HER-2/neu by Generating Vaccine-Specific FasL+ CD4+ T Cells: First Evidence for Intratumor Apoptotic Regulatory T Cells.  Cancer Research 70:2686 [PubMedID: 20233867]

Gritzapis, AD. et al.(2008). Identification of a novel immunogenic HLA-A*02:01-binding epitope of HER-2/neu with potent antitumor properties. J Immunol. 181: 146-154 PubMedID: 18566379]

A*02:01/LIAHNQVRQV (Her-2(10))

Grolleau-Julius, A. et al. (2008). Impaired dendritic cell function in aging leads to defective antitumor immunity. Cancer Res 68: 6341-6349 [PubMedID: 18676859]

H-2Kb/SIINFEKL (Ovalbumin)

Guo, W. et al. (2012) HLA-Mismatched Stem-Cell Microtransplantation As Postremission Therapy for Acute Myeloid Leukemia: Long-Term Follow-Up. Journal of Clinical Oncology 30: 4084-4090. [PubMedID: 23045576]

Guo, W. et al. (2010) Pentamer guided HLA-restricted epitope identification for mucoprotein 4 antigen of pancreatic duct adenocarcinoma. Zhonghua Wai Ke Za Zhi. 48: 1416-1424 [PubMedID: 21092580]

A*02:01/ELAGIGILTV (MelanA / MART-1)

Hakerud, M (2014) Intradermal photosensitisation facilitates stimulation of MHC class-I restricted CD8 T-cell responses of co-administered antigen. Journal of Controlled Release. 174. pp143-50. [PubMedID: 24280261]

H-2Kb/SIINFEKL (Ovalbumin 257-264)

Hansen et al (2011) CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice. Cancer Immunology & Immunotherapy epub ahead of print [PubMedID:22095092]

Hardy, MY. et al. (2009) NK cells enhance the induction of CTL responses by IL-15 monocyte-derived dendritic cells. Immunol. and Cell Biol. 87: 606-614 [PubMedID: 19546878]

A*02:01/ELAGIGILTV (MelanA / MART-1)

Harrop, R. et al. (2007). Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol. Immunother. 57: 977-986. [PubMedID: 18060404]

A*02:01/RLARLALVL (5T4)
A*02:01/FLTGNQLAV (5T4)

He, L. et al.(2005). A sensitive flow cytometry-based cytotoxic T-lymphocyte assay through detection of cleaved caspase 3 in target cells. J. Imm. Methods 304: 43-59. [[PubMedID: 16076473]

A*02:01/SLYNTVATL (HIV-1 gag p17)

Hervas-Stubbs et al (2012) CD8 T Cell Priming in the Presence of IFN-α Renders CTLs with Improved Responsiveness to Homeostatic Cytokines and Recall Antigens: Important Traits for Adoptive T Cell Therapy. Journal of Immunology [PubMedID:22925929]

Himoudi, N. et al. (2008). MYCN as a target for cancer immunotherapy. Cancer Immunol. Immunother. 57: 693-700. [PubMedID: 18004567]


Hirano, F. et al. (2005). Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65: 1089-1096. [PubMedID: 15705911]

H-2Ld/LPYLGWLVF (Tumor antigen P815)


Huang et al (2012) Identification of a New Cytotoxic T-Cell Epitope p675 of Human Telomerase Reverse Transcriptase. Cancer Biotherapy & Radiopharmaceuticals [PubMedID:22917214]

Hunger et al (2011) Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. Cancer Immunology Immunotherapy.  60:1553 [PubMedID:21681371]

Hurez et al (2012) Mitigating Age-Related Immune Dysfunction Heightens the Efficacy of Tumor Immunotherapy in Aged Mice. Cancer Research 72:2089 [PubMedID:22496463]

Inderberg-Suso et al (2012) Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001 OncoImmunnology 1:671

Ishikawa et al (2012) Phase I clinical trial of vaccination with URLC10-derived peptide for patients with advanced esophageal cancer Esophagus 9:104

Iwahashi et al (2010) Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Science 101:2510 [PubMedID:20874827]

Jacobs et al (2011) An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. International Journal of Cancer 128:874 [PubMedID:20473889]

Jones et al (2009) Lentiviral Vector Design for Optimal T Cell Receptor Gene Expression in the Transduction of Peripheral Blood Lymphocytes and Tumor-Infiltrating Lymphocytes Human Gene Therapy 20:630 [PubMedID:19265475]

Kokolus et al (2013) Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature. PNAS 110(50) [PubMedID: 24248371]

Kaida et al (2011) Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract.  Journal of Immunotherapy 34:92 [PubMedID:21150717]

Kaka et al (2009) Genetic Modification of T Cells with IL-21 Enhances Antigen Presentation and Generation of Central Memory Tumor-Specific Cytotoxic T Lymphocytes Journal of Immunotherapy 32:726 [PubMedID:19561536]

Kim, YH. et al. (2008) Combination therapy with cisplatin and anti-4-1BB synergisic anticancer effects and amelioration of cisplatin-induced nephrotoxicity. Cancer Res. 68: 7264-7269 [PubMedID:18794112]

H-2Kb/SIINFEKL (Ovalbumin)

Kim, YH. et al. (2009) Mechanisms involved in synergisitic anticancer effects of anti-4-1BB and cyclophosphamide therapy. Mol. Cancer Ther. 8: 469-478. [PubMedID:19190115]

H-2Kb/SIINFEKL (Ovalbumin)

Kline et al (2012) Cellular and Molecular Requirements for Rejection of B16 Melanoma in the Setting of Regulatory T Cell Depletion and Homeostatic Proliferation Journal of Immunology 188:2360 [PubMedID:22312128]

Koido, S. et al (2013) Augmentation of Antitumor Immunity by Fusions of Ethanol-Treated Tumor Cells and Dendritic Cells Stimulated via Dual TLRs through TGF-b1 Blockade and IL-12p70 Production. PLoS One 8(5) [PubMedID: 23717436]

Koido, S. et al. (2013). Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytes. PLoS One. 8(3): e59280. [PubMedID: TBC]


Koido, S. et al. (2010).  Dendritic/pancreatic carcinoma fusions for clinical use: Comparative functional analysis of healthy- versus patient-derived fusions.  Clinical Immunology. 135, 384-400. [PubMedID:20226739]


Koido, S. et al. (2008). In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells. J. Translational Medicine. 6: 51 [PubMedID:18793383]


Koido, S. et al. (2007). Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells. J. Immunol. 179: 4874-83. [PubMedID:17878387]


Koido, S. et al. (2006). Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells. J. Immunol. 178: 613-622. [PubMedID:17182602]


Koido, S. et al. (2005). Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin. Cancer Res. 11: 7891-7900. [PubMedID:16278414]


Koido, S. et al. (2005). Induction of antigen-specific CD4- and CD8-mediated T-cell responses by fusions of autologous dendritic cells and metastatic colorectal cancer cells. International Journal of Cancer. 117: 587. [PubMedID:15945098]

Kono et al (2012) Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. Journal of Translational Medicine 10:141 [PubMedID:22776426]

Kovalcsik et al (2011) Poly(I:C)-induced tumour cell death leads to DC maturation and Th1 activation. Cancer Immunology & Immunotherapy 60:1609 [PubMedID:21691724]

Krambeck, A.E. et al.(2007). Survivin and B7-H1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin. Cancer Res. 13: 1749-1756. [PubMedID:17363528]

A*02:01/LMLGEFLKL (Survivin)

Kreisel, D. et al. (2010). MHC Class II Expression by Pulmonary Nonhematopoietic Cells Plays a Critical Role in Controlling Local Inflammatory Responses. Journal of Immunology 185: 3809-3813. [PubMedID:20810992]

Kuball et al (2011) Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. Cancer Immunology & Immunotherapy 60:161 [PubMedID:20963411]

Kuball, J. et al. (2007). Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109: 2331-2338. [PubMedID:17082316]

Kumar et al (2011) Increased Sensitivity of Antigen-Experienced T Cells through the Enrichment of Oligomeric T Cell Receptor Complexes. Immunity 35:375 [PubMedID:21903423]

Kumari, S. et al (2014). Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes. PNAS, 111:403 [PubMedID:24344295]

Lee et al (2005) Peptide/MHC Tetramer Analysis. Analyzing T cell Responses p197 (pub. Springer)

Leisegang et al (2010) MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors .Journal of Clinical Investigation 120:3869 [PubMedID:20978348]

Lekka et al (2010) Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy. Cancer Immunology & Immunotherapy 59:715[PubMedID:19904532]

Li et al (2010) Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. European Journal of Immunology. 40:3325 [PubMedID:21072887]

Lin, P-Y. et al. (2010). B7-H1 Dependent Sex-Related Differences in Tumor Immunity and Immunotherapy Responses. J. Immunol. 185: 2747-2753. [PubMedID:20686128]

H-2Kb/SIINFEKL (Ovalbumin)

Liu, K. et al. (2006). CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape. J. Immunol. 176: 3374-3382. [PubMedID:[16517705]

H-2Ld/SPSYVYHQF (MuLV env gp70)

Liu et al (2011) Vaccination with immunoglobulin frame region-derived nonapeptide elicits cellular immune response against lymphoma in human leukocyte antigen-A2.1 transgenic mice. Leukemia and Lymphoma 52:1795 [PubMedID:21657960]

Lladser, A. et al. (2010). DAI (DLM-1/ZBP1) as a Genetic Adjuvant for DNA Vaccines That Promotes Effective Antitumor CTL Activity.  Molecular Therapy 19:394 [PubMedID:21157438]

Lladser, A. et al. (2010). Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma.  Cancer Immunology Immunotherapyy 59:81 [PubMedID:19526360]


Lopes, L. et al. (2008). Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J. Virol. 82: 86-95. [PubMedID: 17959670]


Liu et al. (2007). Generation of cytotoxic T lymphocytes specific for B-cell acute lymphoblastic leukemia family-shared peptides derived from immunoglobulin heavy chain framework region. Chinese Journal of Medicine 120: 652. [PubMedID:  17517179]

Lutz-Nicoladoni et al (2011) Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine. Immunology and Cell Biology. epub ahead of print [PubMedID:21383769]

Maecker (2006) The Role of Immune Monitoring in Evaluating Cancer Immunotherapy. Cancer Drug Discovery and Development p59.

Mandl et al (2011) Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells. Cancer Immunology Immunotherapy  [PubMedID: 21822917]

Masumoto et al. (2006). Allogeneic gastric cancer cell-dendritic cell hybrids induce tumor antigen (carcinoembryonic antigen) specific CD8+ T cells. Cancer Immunology and Immunotherapy 55:131 [PubMedID:15891883]

McKee et al (2012) Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses. Journal of Controlled Release [PubMedID:22386518]

Medina-Echeverz J., et al (2011) Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. Journal of Immunology. 186:807-15 [PubMedID: 21148040]


Medina-Echeverz, J et al (2014) Harnessing High Density Lipoproteins to Block Transforming Growth Factor Beta and to Inhibit the Growth of Liver Tumor Metastases. PloS One. 9(5). e96799. [PubMedID: 24797128]


Meng, J-Z. et al. (2010). Oral Vaccination with Attenuated Salmonella enterica Strains Encoding T-cell Epitopes from Tumor Antigen NY-ESO-1 Induces Specific Cytotoxic T-Lymphocyte Responses. Clinical and Vaccine Immunology. 17(6):884. [PubMedID: 20375244]

A*02:01/SLLMWITQV (NY-ESO157-165)

Mehrotra, S. et al. (2007). Inhibition of c-Jun N-terminal kinase (JNK) rescues influenza epitope-specific human cytolytic T lymphocytes (CTL) from activation-induced cell death (AICD). J. Leukoc. Biol. 81: 539-547. [PubMedID: 17062604]

A*02:01/GILGFVFTL (Influenza A MP)
A*02:01/AAGIGILT (MelanA / MART-1)

Micklethwaite et al (2010) Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood 115:2695 [PubMedID:20110422]

Milne, K. et al. (2008) Tumor-infiltrating T cells correlate with NY-ESO-1 specific autoantibodies in ovarian cancer. PLoS ONE 3: e3409 [PubMedID: 18923710]


Moeller, I. et al. (2008) Dendritic cell maturation with poly(I:C)-based versus PGE2-based cytokine combinations results in differential functional characteristics relevant to clinical application.; J Immunother. 31:506-519.[PubMedID: 18463533]

A*02:01/ELAGIGILTV (MelanA/MART-1)
A*02:01/ALQPGTALL (prostate stem cell antigen)

Moeller et al (2012) Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes Cancer Immology Immunotherapy [PubMedID:22562379]

Mohamed et al (2012) in vitro evaluation of human hybrid cell lines generated by fusion of B-lymphoblastoid cells and ex vivo tumour cells as candidate vaccines for haematological malignancies. [PubMedID:22939910]

Morita et al (2006) Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation. International Journal of Cancer 119:1360.[PubMedID: 16596644]

Napoletano et al (2012) Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation. European Journal of Immunology 42:936 [PubMedID:22531918]

Nellore et al (2014) The cyclin dependent kinase inhibitot (R)-rocovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors. Clinical Immunology. 152(1-2) pp.48-57. [PubMedID: 24631965]


Norell, H. et al. (2009). Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-127-35-Reactive T cells from activation-induced cell death. Cancer Res. 69: 6282-6289 [PubMedID: 19638595]

A*02:01/ELAGIGILTV (MelanA/MART-1)

Olin et al (2011) Oxygen is a Master Regulator of the Immunogenicity of Primary Human Glioma Cells. Cancer Research epub [PubMedID: 21908554]

Olofsson R. et al (2013) Melan-A specific CD8+ T lymphocytes after hyperthermic isolated limb perfusion: A pilot study in patients with in-transit metastases of malignant melanoma. Int. J. Hyperthermia 29(3): 234-238. [PubMedID: 23590363]

Pavlenko, M. et al. (2005). Identification of an immunodominant H-2Db-restricted CTL epitope of human PSA. Prostate 64: 50-59. [PubMedID: 15651071]

H-2Db/HCIRNKSVI (Prostate specific antigen)

Peng, PD. et al. (2009). Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Therapy. 16: 1042-1049.[PubMedID: 19494842]

A*02:01/LLGRNSFEV (p53)

Pinkhasov et al. (2011). TRecombinant plant-expressed tumour-associated MUC1 peptide is immunogenic and capable of breaking tolerance in MUC1.Tg mice. Plant Biotechnology Journal epub [PubMedID: 21740504]

Prestwich, RJ. et al. (2008). Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin. Cancer Res. 14: 7358-7366[PubMedID: 19010851]

A*02:01/ELAGIGILTV (MelanA/MART-1)

Provasi et al (2012) Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer Nature Medicine [PubMedID:22466705]

Provenzano, M. et al. (2006). Characterization of highly frequent epitope-specific CD45RA+/CCR7+/- T lymphocyte responses against p53-binding domains of the human polyomavirus BK large tumor antigen in HLA-A*02:01+ BKV-seropositive donors. J. Transl. Med. 4: 47. [PubMedID: 17096832]

A*02:01/ELAGIGILTV (MelanA/MART 1)

Pufnock, J. et al. (2011). Priming CD8+ T-cells with dendritic cells matured using TLR4 amd TLR7/8 ligands together enhnces generation of CD8+ T-cells retaining CD28. Blood. in press. [PubMedID: 21493800]

A*02:01/ELAGIGILTV (MelanA/MART-1)

Raafat et al (2011) Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope. International Journal of Cancer epub [PubMedID:22116674]

Racanelli et al (2010) Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. Blood 115:1185 [PubMedID:20008301]

Radford, KJ. et al. (2006). CD11c+ blood dendritic cells induce antigen-specific cytotoxic T lymphocytes with similar efficiency compared to monocyte-derived dendritic cells despite higher levels of MHC class I expression. J Immunother. 29: 596-605.[PubMedID: 17063122]

A*02:01/ELAGIGILTV (MelanA/MART-1)
A*02:01/GILGFVFTL (Influenza MP)

Rasmussen et al (2010) Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy. Journal of Immunological Methods 355:52 [PubMedID:20171968]

Rosenthal, R. et al. (2009). Differential responsiveness to IL-2, IL-7 and IL-15 common receptor gchain cytokines by antigen-specific peripheral blood naive or memory cytotoxic CD8+ T cells from healthy donors and melanoma patients. J Immunother. 32: 252-261. [PubMedID: 19242375]

A*02:01/NLVPMVATV (CMV pp65)
A*02:01/ELAGIGILTV (MelanA/MART-1)
A*02:01/SLSAYIIRV (Vaccinia Virus H3L)
A*02:01/KVDDTFYYV (Vaccinia Virus C7L)

Rusakiewicz et al. (2010). Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice. Vaccine 28:6374. [PubMedID:20654669]

Russo, V. et al. (2007). Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity. J. Clin. Invest. 117: 3087-96. [PubMedID:17885685]

H-2Kb/SIINFEKL (Ovalbumin)

Saha et al (2009) Stimulatory effects of CpG oligodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice. International Journal of Cancer 124:877 [PubMedID:19035460]

Saha et al (2010) Combination of CTL-associated Antigen-4 Blockade and Depletion of CD25+ Regulatory T Cells Enhance Tumour Immunity of Dendritic Cell-based Vaccine in a Mouse Model of Colon Cancer. Scandinavian Journal of Immunology 71:70 [PubMedID:20384858]

Sakakibara et al. (2011). Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen. Cancer Immunology and Immunotherapy epub  [PubMedID: 21681375]

Salerno, E. P. et al (2013) Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund’s adjuvant, with or without peptide. Cancer Immunology Immunotherapy epub ahead of print. [PubMedID:23657629]


Sartorius, R. et al. (2008). The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses. J. Immunol. 180: 3719-3728. [PubMedID: 18322177]


Schuler et al (2011) EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma. Journal of Translational Medicine 9:168 [PubMedID:21970318]

Schumacher et al (2005) Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L27Melan-A/MART-126–35 peptide encapsulated into virosomes in vitro. Vaccine 23:5572 [PubMedID:16165256]

Sebestyén, Z. et al. (2008). Human TCR that incorporate CD3c induce highly preferred pairing between TCRa and b chains following gene transfer. J. Immunol. 180: 7736-7746. [PubMedID: 18490778]

A*02:01/YLEPGPVTA (gp100 (pmel17))
A*02:01/ELAGIGILTV (MelanA / MART-1)

Shang et al (2009) Rational optimization of tumor epitopes using in silico analysis-assisted substitution of TCR contact residues. European Journal of Immunology 39:2248 [PubMedID:19593772]

Shinozaki et al (2009) Tumor-specific cytotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti-tumor immunity. International Journal of Cancer 124:1372 [PubMedID:19089917]

Shirota et al (2011) CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity. Cancer Immunology Immunotherapy 60:659 [PubMedID:21318638]

Siegel, S. et al. (2006). Identification of HLA-A*02:01-presented T cell epitopes derived from the oncofetal antigen-immature Laminin receptor protein in patients with hematological malignancies. J. Immunol. 176: 6935-6944. [PubMedID:16709854]

Slagter-Jager, J. G. et al. (2013). Evaluation of RNA amplification methods to improve DC immunotherapy antigen presentation and immune response. Mol. Therapy Nucleic Acids 2:e91. [PubMedID:23653155]

A*02:01/ELAGIGILTV (MelanA / MART 26-35)

Soderquest, K., et al. (2011). Cutting Edge: CD8+ T Cell Priming in the Absence of NK Cells Leads to Enhanced Memory Responses. J. Immunol. 186: 3304. [PubMedID:21307295]

Soeda, A. et al (2010). Long-Term Administration of Wilms Tumor-1 Peptide Vaccine in Combination with Gemcitabine Causes Severe Local Skin Inflammation at Injection Sites. Jpn. J. Clin. Oncol. 40: 1184-1188. [PubMedID: 20656693]

Soeda, A. et al (2009). Regular dose of Gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn. J. Clin. Oncol. 39: 797-806. [PubMedID: 19797418]

A*02:01/NLVPMVATV (CMV pp65)
A*02:01/RMFPNAPYL (WT-1)
A*24:02/CMTWNQMNL (WT-1)

Sommermeyer, D. and Uckert, W.(2010). Minimal Amino Acid Exchange in Human TCR constant Regions Fosters Improved Function of TCR Gene-Modified T Cells. Journal of Immunology. 184:6223-6231. [PubMedID: 20483785]

A*0201/SLLMWITQV (NY-ESO157-165)

Spies et al (2011) An Artificial PAP Gene Breaks Self-tolerance and Promotes Tumor Regression in the TRAMP Model for Prostate Carcinoma. Molecular Therapy epub ahead of print [PubMedID:22086231]

Straetemans et al (2012) TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune Targets Clinical and Developmental Immunology 2012:586314 [PubMedID:22400038]

Stec et al. (2012). Properties of Monocytes generated from haematopoietic CD34+ stem cells from bone marrow of colon cancer patients. Cancer Immunology Immunotherapy epub. [PubMedID:23180014]


HER2/neu 369-377)

Steitz, J. et al. (2006). Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination. Cancer Gene Ther. 13: 318-325. [PubMedID:16151477]

H-2Kb/SIINFEKL (Ovalbumin)

Stoitzner, P. et al. (2008). Tumor immunotherapy by epicutaneous immunization requires langerhans cells. J. Immunol. 180: 1991-8. [PubMedID:18209098]

H-2Kb/SIINFEKL (ovalbumin)

Stronen, E. et al (2009). Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumor cells. Scandinavian Journal of Immunology. 69: 319-328 [PubMedID: 19284496]

A*02:01/ELAGIGILTV (MelanA/MART-1)
A*02:01/LLWAGALAM (CD33)
A*02:01/VLWHWLLRT (CD19)
A*02:01/NLVPMVATV (CMV pp65)

Suso et al. (2011). hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol Immunotherapy 60:809 [PubMedID: 21365467]

Takata et al. (2011). Frequency of CD45RO+ subset in CD4+CD25high regulatory T cells associated with progression of hepatocellular carcinoma. Cancer Letters 307:165 [PubMedID: 21530074]

Theoret, MR. et al. (2008). Relationship of p53 overexpression on cancers and recognition by anti-p53 TCR transduced T cells. Human Gene Therapy. 19(11):1219-1232. [PubMedID: 18707199]

A*02:01/LLGRNSFEV (p53)
A*02:01/KTWGQYWQV (gp100)

Thomas, S. (2014) Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials. 35. pp 814-824. [PubMedID: 24144906]


Thiel et al. (2011). Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells. Br J Cancer 105:596 [PubMedID: 21829207]

Tomihara, K. et al. (2010).  Antigen-Specific Immunity and Cross-Priming by Epithelial Ovarian Carcinoma-Induced CD11b+Gr-1+ Cells [PubMedID: 20427766]

H-2Kb/SIINFEKL (Ovalbumin)

Uhlin, M. and Mattsson, J. (2011). In vitro or in vivo expansion before adoptive T-cell therapy? Immunotherapy. 3:131-133 [PubMedID: 21322751]

Uhlin, M. et al. (2009). A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunology and Immunotherapy. 59(3):473-7 [PubMedID: 19908041]

van der Most, R. et al.  (2010) Cyclophosphamide Chemotherapy Sensitizesm Tumor Cells to TRAIL-Dependent CD8 T Cell-Mediated Immune Attack Resulting in Suppression of Tumor Growth.  PLoS ONE 4(9):e6982 [PubMedID: 19746156]

Waeckerle‐Men et al (2006) Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunology Immunotherapy 55:1524 [PubMedID:16612599]

Wang et al (2011) CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. Journal of Clinical Investigation 121:2731  [PubMedID: 21537079]

Wang Q., et al (2011) Mutant proteins as cancer-specific biomarkers. Proc Natl Acad Sci U S A. 108(6):2444-9. [PubMedID: 21248225]

Wang, Z. et al.  (2010) Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.  Chin Med J 123: 912-916 [PubMedID: 20497687]

A*24:02/CMTWNQMNL (WT1 p235)

Webb, J. et al. (2010). Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (aE/b7 Integrin) in high-grade serious ovarian cancer. Gynecologic Oncology. 118:228-236. [PubMedID:20541243]


Weber, G. et al. (2009). WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation. Leukemia. 23: 1634-1642 [PubMedID: 19357702]

A*02:01/RMFPNAPYL (WT1 p126)
A*02:01/CMTWNQMNL (WT1 p235)

Wei, L. et al. (2010). Comarison of Wilms' tumour antigen 1-specific T lymphocyte generation soon after nonmyeloablative allergenic stem-cell transplantation in acute and chronic leukemia patients. International Journal of Hematology. 91 652-60. [PubMedID: 20376582]

Wei L., et al (2011) WT1-specific CTL cells of recipient origin may exist in the peripheral blood of patients achieving full donor chimerism soon after nonmyeloablative transplantation.  Clinical Transplantation. [PubMedID: 21269328]


Wenandy, L. et al. (2008). The immunogenicity of the hTERT540-548 peptide in cancer. Clin. Cancer Res. 14: 4-7. [PubMedID: 18172245]


Weng, L. et al. (2011). Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. Int Journal Cancer. in press. [PubMedID: 21154809]

West, E. et al. (2009) Clinical grade OK432-activated dendritic cells. In vitro characterization and tracking during intralymphatic delivery. J Immunother. 32: 66-78. [PubMedID: 19307995]

A*02:01/ELAGIGILTV (MelanA/MART-1)

Wiesner, M. et al. (2008). Conditional immortalization of human B cells by CD40 ligation. PLoS ONE 3(1): e1464. [PubMedID: 18213373]

A*02:01/ELAGIGILTV (MelanA / MART-1)

Wilkinson et al. (2011). Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients. Cancer Immunology Immunotherapy epub [PubMedID: 21874303]

Wilkinson, R. et al. (2006). Numerical and functional assessment of blood dendritic cells in prostate cancer patients. The Prostate 66: 180-192. [PubMedID: 16173035]

A*02:01/GILGFVFTL (Influenza A MP)

Winkler et al (2012) Hodgkin's lymphoma RNA-transfected dendritic cells induce cancer/testis antigen-specific immune responses.Cancer Immology Immunotherapy [PubMedID:22419371]

Wölfl et al (2010) Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy.Cancer Immunology & Immunotherapy 60:173 [PubMedID:20972785]

Wolfl, M. et al. (2007). Activation-induced expression of CD137 permits detection, isolation and expansion of the full repertoire of CD8+ T-cells responding to antigen without requiring knowledge of epitope-specificities. Blood 110: 201-210. [PubMedID: 17371945]

A*02:01/ELAGIGILTV (MelanA / MART-1)
B*07:02/TPRVTGGGAM (HCMV pp65)

Wurzenberger et al (2009) Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo. Cancer Immunology Immunotherapy 58:901 [PubMedID:18953536]

Wysocki et al (2010) Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer 17:465 [PubMedID:20168352]

Wysocki, PJ. et al. 2006). Captopril, an Angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice. Clin. Cancer Res. 12: 4095-4102. [PubMedID:16818710]


Xia et al (2012) High-Intensity Focused Ultrasound Tumor Ablation Activates Autologous Tumor-Specific Cytotoxic T Lymphocytes. Ultrasound in Medicine and Biology 38:1363 [PubMedID:22633269]

Xie et al (2010) Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity. Cancer Biotherapy & Radiopharmaceuticals 25:21 [PubMedID:20187793]

Xiong et al (2010) Novel cancer vaccine based on genes of Salmonella pathogenicity island 2. International Journal of Cancer 126:2622 [PubMedID:19824039]

Xu et al (2011) Expansion of interferon-gamma-producing multifunctional CD4+ T-cells and dysfunctional CD8+ T-cells by glypican-3 peptide library in hepatocellular carcinoma patients. Clinical Immunology 139:302 [PubMedID:21419713]

Xu et al (2009) Recombinant E. coli LLO/OVA vaccination effectively inhibits murine melanoma metastasis to lung by CD8+T cells immunity. Chinese Journal of Cancer Research 21:44

Yagi, H. et al. (2006). Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization. Cancer. Res. 66: 10136-10144. [PubMedID:17047078]


Yan, M. et al. (2008). Development of cellular immune responses against PAX5, a novel target for cancer immunotherapy. Cancer Res. 68: 8058-8065 [PubMedID: 18829564]


Yang, S. et al. (2008). Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cells. Cancer Immunol. Immunother. 58: 503-513. [PubMedID: 18690438]


Yasuda, T. et al. (2007). Superior anti-tumor protection and therapeutic efficacy of vaccination with allogenic and semiallogenic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol. Immunother. 56: 1025-36. [PubMedID:17131118]

H-2Ld/SPSYVYHQF (muLV envgp70)
H-2Ld/TPHPARIGL (E. Coli b-galactosidase)

Yoshikawa, T. et al (2011). HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.  Cancer Science. 102: 918-925. [PubMedID: 21281401]

Yoshitake, Y. et al. (2015) Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clinical Cancer Research. 21(2): 312-21. [PubMedID: 25391695]

Zaini, J. et al. (2007). OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice. J. Clin. Invest. 117: 3330-8. PubMedID: 17975668]

H-2Kb/SIINFEKL (Ovalbumin)

Zeng et al (2012) Enhancing Immunostimulatory Function of Human Embryonic Stem Cell-Derived Dendritic Cells by CD1d Overexpression Journal of Immunology [PubMedID:22407918]

Zhang, L. et al (2013) CD20 ligation reverses T cell tolerance in acute myeloid leukemia. J. Clin. Invest. Epub ahead of print. [PubMedID: TBC]

H-2Kb/SIINFEKL (Ovalbumin 257-264)

Zhang et al (2011) Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials 32:3666 [PubMedID: 21345488]

Zhu, Y., et al (2010). T-bet and Eomesodermin Are Required for T Cell-Mediated Antitumour Immune Responses.  Journal of Immunology. 185: 3174-3183. [PubMedID: 20713880]

Zizzari et al (2011) HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy. Journal of Molecular Medicine. epub [PubMedID: 21845448]

(back to top)